Literature DB >> 20356997

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.

Z F Udwadia, T Sen, G Moharil.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20356997     DOI： 10.1183/09031936.00132009

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  11 in total

1.  Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Authors:  Robert S Wallis; Wesley Jakubiec; Vikas Kumar; Gabriella Bedarida; Annette Silvia; Darcy Paige; Tong Zhu; Mark Mitton-Fry; Lynn Ladutko; Sheldon Campbell; Paul F Miller
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Xin Zhang; Matthew E Falagas; Konstantinos Z Vardakas; Rui Wang; Rong Qin; Jin Wang; Youning Liu
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

3.  Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

Authors:  Gaëlle Guiewi Makafe; Yuanyuan Cao; Yaoju Tan; Mugweru Julius; Zhiyong Liu; Changwei Wang; Moses M Njire; Xingshan Cai; Tianzhou Liu; Bangxing Wang; Wei Pang; Shouyong Tan; Buchang Zhang; Wing Wai Yew; Gyanu Lamichhane; Jintao Guo; Tianyu Zhang
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review.

Authors:  Alena Tse-Chang; Dennis Kunimoto; Evelina Der; Rabia Ahmed
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

5.  Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Authors:  Zhiyi Lan; Nafees Ahmad; Parvaneh Baghaei; Linda Barkane; Andrea Benedetti; Sarah K Brode; James C M Brust; Jonathon R Campbell; Vicky Wai Lai Chang; Dennis Falzon; Lorenzo Guglielmetti; Petros Isaakidis; Russell R Kempker; Maia Kipiani; Liga Kuksa; Christoph Lange; Rafael Laniado-Laborín; Payam Nahid; Denise Rodrigues; Rupak Singla; Zarir F Udwadia; Dick Menzies
Journal:  Lancet Respir Med       Date:  2020-03-17       Impact factor: 30.700

6.  Pharmacodynamic Correlates of Linezolid Activity and Toxicity in Murine Models of Tuberculosis.

Authors:  Kristina M Bigelow; Amelia N Deitchman; Si-Yang Li; Kala Barnes-Boyle; Sandeep Tyagi; Heena Soni; Kelly E Dooley; Rada M Savic; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2021-06-04       Impact factor: 5.226

7.  Linezolid for drug-resistant pulmonary tuberculosis.

Authors:  Bhagteshwar Singh; Derek Cocker; Hannah Ryan; Derek J Sloan
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

8.  Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France.

Authors:  Marie Jaspard; Nathalie Butel; Najoua El Helali; Dhiba Marigot-Outtandy; Helene Guillot; Gilles Peytavin; Nicolas Veziris; Bahram Bodaghi; Philippe Flandre; Gregoire Petitjean; Eric Caumes; Valerie Pourcher
Journal:  Emerg Infect Dis       Date:  2020-08       Impact factor: 6.883

Review 9.  Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.

Authors:  Akosua Adom Agyeman; Richard Ofori-Asenso
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-06-22       Impact factor: 3.944

10.  Linezolid-Associated Optic Neuropathy in Drug-Resistant Tuberculosis Patients in Mumbai, India.

Authors:  Salil Mehta; Mrinalini Das; Chinmay Laxmeshwar; Sylvie Jonckheere; Sein Sein Thi; Petros Isaakidis
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.